filings.toolsItem 16. FORM 10-K SUMMARY
4K characters. Original on sec.gov · Markdown
Item 16. FORM 10-K SUMMARY
None.
| Pfizer Inc. | 2023 Form 10-K | 114 |
SIGNATURES
Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
| Pfizer Inc. | |||||||||||
| Dated: February 22, 2024 | By: | /S/ MARGARET M. MADDEN | |||||||||
| Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel |
We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Signature | Title | Date | ||||||||||||
| /S/ ALBERT BOURLA Albert Bourla | Chairman, Chief Executive Officer and Director (Principal Executive Officer) | February 20, 2024 | ||||||||||||
| /S/ DAVID M. DENTON David M. Denton | Chief Financial Officer, Executive Vice President (Principal Financial Officer) | February 20, 2024 | ||||||||||||
| /S/ JENNIFER B. DAMICO Jennifer B. Damico | Senior Vice President and Controller (Principal Accounting Officer) | February 20, 2024 | ||||||||||||
| /S/ RONALD E. BLAYLOCK Ronald E. Blaylock | Director | February 21, 2024 | ||||||||||||
| /S/ SUSAN DESMOND-HELLMANN Susan Desmond-Hellmann | Director | February 21, 2024 | ||||||||||||
| /S/ JOSEPH J. ECHEVARRIA Joseph J. Echevarria | Director | February 20, 2024 | ||||||||||||
| /S/ SCOTT GOTTLIEB Scott Gottlieb | Director | February 21, 2024 | ||||||||||||
| /S/ HELEN H. HOBBS Helen H. Hobbs | Director | February 20, 2024 | ||||||||||||
| /S/ SUSAN HOCKFIELD Susan Hockfield | Director | February 20, 2024 | ||||||||||||
| /S/ DAN R. LITTMAN Dan R. Littman | Director | February 20, 2024 | ||||||||||||
| /S/ SHANTANU NARAYEN Shantanu Narayen | Director | February 20, 2024 | ||||||||||||
| /S/ SUZANNE NORA JOHNSON Suzanne Nora Johnson | Director | February 20, 2024 | ||||||||||||
| /S/ JAMES QUINCEY James Quincey | Director | February 21, 2024 | ||||||||||||
| /S/ JAMES C. SMITH James C. Smith | Director | February 20, 2024 |
| Pfizer Inc. | 2023 Form 10-K | 115 |
Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES